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Cell senescence is an antiviral 
defense mechanism
Maite Baz-Martínez1, Sabela Da Silva-Álvarez2, Estefanía Rodríguez3, Jorge Guerra4, 
Ahmed El Motiam1, Anxo Vidal5, Tomás García-Caballero6, Miguel González-Barcia7,8, 
Laura Sánchez4, César Muñoz-Fontela3,9, Manuel Collado2,* & Carmen Rivas1,10,*
Cellular senescence is often considered a protection mechanism triggered by conditions that impose 
cellular stress. Continuous proliferation, DNA damaging agents or activated oncogenes are well-known 
activators of cell senescence. Apart from a characteristic stable cell cycle arrest, this response also 
involves a proinflammatory phenotype known as senescence-associated secretory phenotype (SASP). 
This, together with the widely known interference with senescence pathways by some oncoviruses, had 
led to the hypothesis that senescence may also be part of the host cell response to fight virus. Here, we 
evaluate this hypothesis using vesicular stomatitis virus (VSV) as a model. Our results show that VSV 
replication is significantly impaired in both primary and tumor senescent cells in comparison with non-
senescent cells, and independently of the stimulus used to trigger senescence. Importantly, we also 
demonstrate a protective effect of senescence against VSV in vivo. Finally, our results identify the SASP 
as the major contributor to the antiviral defense exerted by cell senescence in vitro, and points to a role 
activating and recruiting the immune system to clear out the infection. Thus, our study indicates that 
cell senescence has also a role as a natural antiviral defense mechanism.
Cellular senescence is a stable state of proliferative arrest, initially described as the result of proliferative exhaus-
tion in vitro and thought to represent cellular aging1. The cellular senescence program can be activated by a 
variety of cell-intrinsic and -extrinsic stresses including serial passage in vitro, DNA damage caused by chem-
otherapeutic drugs, or the expression of activated oncogenes among others2. Recently, programmed cell senes-
cence during embryonic development was shown to contribute to tissue remodeling and morphogenesis of the 
embryo3,4, suggesting an evolutionary origin of the process that was co-opted as a useful cell response in the 
adult5. Senescent cells arrest at the G0/G1 phase of the cell cycle and are characterized by distinctive phenotypic 
alterations, including enlarged and flattened morphology, enlarged and multinucleated nuclei, and increased 
senescence-associated beta-galactosidase (SA-beta-gal) activity6. In addition, senescent cells secrete a variety of 
factors to the extracellular environment, collectively known as the senescence-associated secretory phenotype 
(SASP). This SASP serves to reinforce the senescence arrest in an autocrine manner, but it can also induce growth 
arrest in a paracrine manner7. SASP components are mainly proinflammatory cytokines and chemokines, growth 
factors, and extracellular matrix remodeling enzymes that can alter the tissue microenvironment and interact 
with the immune system promoting the recognition and clearance of senescent cells, thereby facilitating the 
resolution of the damage.
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The proinflamatory properties of senescent cells as well as the fact that some viruses have evolved mechanisms 
to inhibit the senescence process has led to hypothesize that cell senescence may have evolved as an antiviral 
defense mechanism8. The induction of senescence in response to interferon treatment9 and the role that endoge-
nous interferon-beta induced by DNA damage10 plays in induction of senescence also reinforce this hypothesis.
Here, we explored whether cell senescence plays a role in the host response to viral infection. We found 
that the replication of vesicular stomatitis virus (VSV) is significantly impaired in senescent cells compared to 
their non-senescent counterparts. Consistently, we demonstrate that senescence helps to control VSV infection 
in vivo. Finally, we show that the SASP mediates most of the antiviral response and at the same time contributes 
to activate and recruit the immune system for efficient clearance of the virus. These findings lead us to conclude 
that cellular senescence protects the organism against virus infection.
Results
Replicative senescent mouse fibroblasts are resistant to VSV infection. Cell senescence can result 
from the activation of different pathways in response to a variety of stressors2. We decided to evaluate first whether 
senescence triggered by a well-established cell-intrinsic mechanism, such as replicative senescence, can function 
as an antiviral mechanism. Mouse embryo fibroblasts (MEFs) were serially passaged until cell cultures stopped 
growing and acquired the characteristic senescent morphology showing enlarged and flattened cells (Fig. 1A, B). 
Then, we analyzed the cells for the expression of the senescence marker senescence-associated beta-galactosidase 
(SA-beta-gal)11. As expected, senescence-arrested MEFs showed increased SA-beta-gal (Fig. 1B).
To test whether replicative senescent cells were more resistant to VSV infection, serially-passaged, or 24 h 
serum-deprived MEFs were infected with VSV at a multiplicity of infection (MOI) of 0.05 PFU/cell. We quan-
tified VSV particle production at different times after infection by titration of cell supernatants as a measure of 
virus replication. As shown in Fig. 1C, the titer of virus recovered from replicative senescent MEFs was signifi-
cantly lower than that recovered from non-senescent MEFs (2.05 × 105 PFU/mL in senescent cells compared to 
2.75 × 107 PFU/mL in non-senescent cells, p = 0.008, after 36 h of infection), indicating that replicative senescence 
limits the replication of VSV in primary mouse cells. This idea was further corroborated by direct inspection of 
viral protein synthesis after infection of replicative senescent or 24 h serum-deprived MEFs with VSV at a low or a 
high MOI (0.05 or 10 PFU/cell, respectively) (Fig. 1D). Viral protein synthesis production in the senescent MEFs 
was clearly lower than in non-senescent MEFs, independently of the MOI tested (Fig. 1D). VSV infection kills 
infected cells primarily via induction of apoptosis12. Thus, we also evaluated the induction of apoptosis triggered 
after 24 h of infection with VSV at a MOI of 10 in senescent versus non-senescent MEFs. As shown in Fig. 1E, the 
levels of apoptosis detected in the replicative senescent MEFs after VSV infection were significantly lower than 
those detected in the non-senescent MEFs (2.03% in senescent cells compared to 8.4% in non-senescent ones, 
p = 0.048). All together, these results indicated that replication of VSV was limited in replicative senescent MEFs 
compared to non-senescent cells.
Chemotherapy-induced senescence of human tumor cells restricts VSV infection. To test whether the 
observed resistance to viral infection was a particular feature of mouse cells or specific of senescence-inducing 
stimulus, we decided to test the viral infection of the human lung adenocarcinoma cell line, A549, rendered 
senescent by treatment with the chemotherapeutic DNA damaging agent, bleomycin13. For this, we first treated 
A549 cells with bleomycin for 5 days and then we evaluated cells for the presence of cell senescence markers. 
Bleomycin-treated cells showed increased SA-beta-gal activity and cell size (Fig. 2A), indicative of senescence 
induction. In addition, we observed elevated expression of the tumor suppressor p53 and of the CDK inhibi-
tor p21Cip1 by Western-blot analysis (Fig. 2B), and of the CDKN1A mRNA (the gene coding for p21Cip1) by 
qRT-PCR (Fig. 2C), indicative of activation of the typical tumor suppressor pathways involved in cell senescence6,
Then, bleomycin-induced senescent or 24 h serum-deprived A549 cells were infected with VSV at a MOI of 
0.5 PFU/cell, and viral titers in supernatants recovered from infected cells were evaluated at different times after 
VSV infection. As shown in Fig. 2D, bleomycin treatment induced a statistically significant decrease in viral titers 
in comparison with untreated cells (9.23 × 105 PFU/mL in senescent A549 versus 4.90 × 106 PFU/mL in control 
non-senescent A549 cells after 24 h of infection, p-value = 0.006), again indicating that senescence has a role in the 
control of VSV replication. This notion was further corroborated by direct inspection of viral protein synthesis by 
Western-blot of cell extracts after infection of bleomycin-induced senescent or 24 h serum-deprived A549 cells, with 
VSV at low or high MOIs (0.05 and 10 PFU/cell, respectively) (Fig. 2E). While VSV protein synthesis was observed 
in control cells, viral proteins were virtually undetectable in senescent A549 cells infected with VSV at the low MOI 
of 0.05 PFU/cell (Fig. 2E, upper panel). At the high MOI of 10 PFU/cell, VSV proteins were detected in senescent 
A549 cells, but viral protein levels were clearly lower than those observed in the control A549 cells (Fig. 2E, lower 
panel). Moreover, we also evaluated the effect of bleomycin treatment on the susceptibility of MEFs to VSV replica-
tion. We first treated MEFs with bleomycin for 5 days and then we evaluated cells for senescence marker SA-beta-gal 
activity. As expected, bleomycin-treated MEFs showed increased SA-beta-gal (Fig. 2F), indicative of senescence 
induction. Bleomycin-treated or 24 h serum deprived MEFs were then analyzed for their viral titers in a similar 
manner as described above for A549 cells, obtaining similar results (Fig. 2G). To further substantiate our findings, 
we also evaluated the induction of apoptosis triggered by virus infection in the senescent and control A549 cells, 24 h 
after infection with VSV at a MOI of 10 PFU/cell. As shown in Fig. 2H, the levels of apoptosis detected in the A549 
non-senescent cells after VSV infection were significantly higher than those detected in the senescent A549 cells 
(11.32% compared to 2.75%, respectively, p = 0.012). These results indicated that senescent A549 cells were signif-
icantly more resistant to VSV infection than the non-senescent ones. All together, similarly to what was observed 
for replicative senescent mouse cells, human tumor cells and mouse primary cells rendered senescent by the DNA 
damaging agent bleomycin were also less susceptible to VSV infection than non-senescent cells.
www.nature.com/scientificreports/
3Scientific RepoRts | 6:37007 | DOI: 10.1038/srep37007
Reduced replication of VSV in oncogene-induced senescent MCF7 cells. Our results indicated 
that intrinsic senescence in primary cells and chemotherapy-induced senescence in primary or tumor cells, func-
tion as an antiviral defense mechanism. We then decided to evaluate another well-known senescence-inducing 
stimulus, in particular oncogene-induced senescence14. We first developed an inducible expression system of 
H-RasV12 in MCF7cells. These cells carry a vector for H-RasV12 that allows inducible expression of the onco-
gene upon doxycycline addition to the cell culture medium15. Addition of doxycycline to MCF7-RAS cells pro-
duced a dramatic morphological change that resembles cell senescence (Fig. 3A). SA-beta-gal staining of these 
cultures showed a clear positive staining when H-Ras was induced compared to the non-treated cells (Fig. 3A). 
We also verified H-Ras expression and the activation of its downstream MAPK signaling pathway by analysis of 
the phosphorylated form of ERK by Western-blot after doxycycline treatment (Fig. 3B). In addition, we confirmed 
the senescence induction by checking the increased levels of p53 and p21 protein (Fig. 3B) and of the CDKN1A 
mRNA (Fig. 3C). Then, Ras-induced senescent or 24 h serum deprived untreated MCF7 cells were infected with 
VSV at a MOI of 0.05 or 10 and, at different times after infection, the synthesis of VSV proteins was analyzed 
by Western-blot. As shown in Fig. 3D, the synthesis of VSV proteins was detected in non-senescent MCF7 cells 
Figure 1. Replicative senescent mouse fibroblasts are resistant to VSV infection. (A) Growth curve of 
serially-passaged MEFs showing accumulated population doublings (PDLs) with time. (B) Microscopy images 
of serially-passaged MEFs showing morphology (left panels) and SA-beta-gal staining (right panels) of early 
passage (upper panels) and late passage senescent (bottom panels) MEFs. Quantification of the SA-beta-gal 
positive cells is shown below (at least 200 cells were counted per condition). (C) Viral titers (PFU/mL)  
determined in early or late passage senescent MEFs after the indicated periods of infection (hours post 
infection, hpi) at a multiplicity of infection (MOI) of 0.05 PFU/cell. (D) Western-blot analysis of VSV protein 
synthesis in early or late passage senescent MEFs after the indicated periods of infection at MOIs of 0.05 PFU/
cell (upper panel) or 10 PFU/cell (lower panel). Actin is shown as loading control. (E) Percentage of apoptotic 
cells measured after mock or VSV infection at MOI of 10 PFU/cell, in early or late passage senescent MEFs. 
Data are mean values + /− SE from at least three different experiments. *p < 0.05, **p < 0.01, ***p < 0.001 
Student’s t test.
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Figure 2. Chemotherapy-induced senescence of human tumor cells restricts VSV infection. (A) Microscopy 
images of human tumor A549 cells showing morphology (left panels) and SA-beta-gal staining (right panels) 
of untreated (A549-NT, upper panels) and bleomycin-induced senescent (A549-B, bottom panels) A549 cells. 
Quantification of the SA-beta-gal positive cells is shown below (at least 200 cells were counted per condition). 
(B) Western-blot analysis of senescence markers p53 and p21 in untreated A549 cells (A549-NT) or after 
bleomycin treatment of A549 cells (A549-B). GAPDH is shown as loading control. (C) Expression levels 
of CDKN1A (coding for p21) mRNA relative to GAPDH (x10−3) as determined by qRT-PCR in untreated 
(A549-NT) or bleomycin-treated (A549-B) A549 cells. (D) Viral titers (PFU/mL) determined in untreated 
(A549-NT) or bleomycin-treated (A549-B) A549 cells after the indicated periods of infection at a MOI of 
0.5 PFU/cell. (E) Western-blot analysis of VSV protein synthesis in untreated (A549-NT) or bleomycin-treated 
(A549-B) A549 cells after the indicated periods of infection at MOIs of 0.05 PFU/cell (upper panel) or 10 PFU/
cell (lower panel). Actin is shown as loading control. (F) Microscopy images of MEFs showing morphology (left 
panels) and SA-beta-gal staining (right panels) of untreated (MEFs-NT, upper panels) and bleomycin-induced 
senescent (MEFs-B, bottom panels) MEFs. Quantification of the SA-beta-gal positive cells is shown below (at 
least 200 cells were counted per condition). (G) Viral titers (PFU/mL) determined in untreated (MEFs-NT) or 
bleomycin-treated (MEFs-B) MEFs after the indicated periods of infection at MOIs of 0.05 PFU/cell (left panel) 
or 10 PFU/cell (right panel). (G) Percentage of apoptotic cells measured after mock or VSV infection at MOI of 
10 PFU/cell, in untreated (A549-NT) or bleomycin-treated (A549-B) A549 cells. Data are mean values + /− SE 
from at least three different experiments. *p < 0.05, **p < 0.01, ***p < 0.001 Student’s t test.
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infected with VSV at a MOI of 0.05 or 10. However, we did not detect VSV protein synthesis in the senescent 
cells (Fig. 3D), indicating that expression of H-RasV12 induced resistance of MCF7 cells to VSV replication. In 
summary, these results clearly indicate that senescence induction, independently of the stimulus responsible for 
triggering the response and in both, human and mouse cells, restricts viral infection.
Senescence reduces the cell infectivity of VSV. Our results showed that senescence reduces the effi-
cient production of viral particles. Among many possibilities, this could potentially originate from an early event 
decreasing senescent cell infectivity. To directly assess this possibility, we decided to use A549 cells treated or 
not with bleomycin, as described above, and exposed to a recombinant VSV expressing GFP (rVSV-GFP). After 
incubation of the cells with the rVSV-GFP at a low MOI (0.1 PFU/cell), we evaluated the spreading of the virus 
in the cell culture by immunofluorescence at different times after infection. As shown in Fig. 4A, 24 h after infec-
tion virtually all the control non-senescent A549 cells were infected with rVSV-GFP. In contrast, some senescent 
cells still remained uninfected, proving that senescent cells were less infected by VSV. Then, bleomycin-treated 
or untreated A549 cells were infected with rVSV-GFP at a higher MOI of 0.5 PFU/cell, and 6 or 24 h after infec-
tion we quantified the percentage of rVSV-GFP-positive cells by FACS. Interestingly, we observed a significant 
reduction in the percentage of GFP-positive senescent cells relative to the GFP-positive non-senescent cells at 
both times tested (Fig. 4B). Similarly, with a different experimental system, this time using replicative senescent 
MEFs, we also observed a reduction in the percentage of rVSV-GFP positive senescent cells compared to the 
non-senescent MEFs at 6 h after infection with VSV at MOIs of 0.05 or 0.5 PFU/cell (Fig. 4C). These results 
pointed to an early defect in senescent cells that already impairs viral infection. In addition, we also analyzed the 
Figure 3. Reduced replication of VSV in oncogene-induced senescent MCF7 cells. (A) Microscopy images 
of human tumor MCF7 cells showing morphology (left panels) and SA-beta-gal staining (right panels) of 
untreated (MCF7-NT, upper panels) and H-Ras-induced senescent MCF7 cells (MCF7-RAS, bottom panels). 
Quantification of the SA-beta-gal positive cells is shown below (at least 200 cells were counted per condition). 
(B) Western-blot analysis of H-Ras and downstream targets ERK/P-ERK, and of senescence markers p53 and 
p21 in untreated (MCF7-NT) or after H-Ras induction (MCF7-RAS) MCF7 cells. GAPDH is shown as loading 
control. (C) Expression levels of CDKN1A (coding for p21) mRNA relative to GAPDH (x10−3) as determined by 
qRT-PCR in untreated (MCF7-NT) or H-Ras-induced (MCF7-RAS) MCF7 cells. (D) Western-blot analysis of 
VSV protein synthesis in untreated (MCF7-NT) or H-Ras-induced (MCF7-RAS) MCF7 cells after the indicated 
periods of infection at MOIs of 0.05 PFU/cell (left panel) or 10 PFU/cell (right panel). Tubulin is shown as 
loading control. Data are mean values + /− SE from at least three different experiments. *p < 0.05, **p < 0.01, 
***p < 0.001 Student’s t test.
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evolution of the VSV-GFP infection by video time-lapse microscopy (Fig. 4D) in bleomycin-treated or untreated 
A549 cells infected at a high MOI (10 PFU/cell). Quantification of the intensity of GFP associated fluorescence, 
attributable to VSV replication, per infected cell along the experiment revealed that the GFP signal in the infected 
senescent cells is consistently less intense and evolves more slowly than in the non senescent cells (Fig. 4E). These 
results clearly establish that senescent cells are not only more resistant to be infected but also less permissive to 
viral replication.
The senescence-induced antiviral response is partially mediated by the SASP. One of the prop-
erties of the senescent cells is the secretory phenotype7. Senescent cells secrete a variety of proteins including 
Figure 4. Senescence reduces the cell infectivity of VSV. (A) Fluorescent microscopy images of control 
untreated (A549-NT, left panels) or senescent bleomycin-treated (A549-BLEO, right panels) human tumor 
A549 cells showing virus spread at different times after infection with recombinant VSV expressing GFP (rVSV-
GFP). (B) Percentage of rVSV-GFP positive cells after 6 or 24 hours post infection in control untreated (black 
bars) or senescent bleomycin-treated (white bars) human tumor A549 cells. (C) Percentage of rVSV-GFP 
positive cells after infection with MOIs of 0.05 or 0.5 PFU/cell in control early passage (black bars) or senescent 
late passage (white bars) MEFs. (D) Representative images of control (A549-NT, left panels) or bleomycin-
induced senescent (A549-BLEO, right panels) A549 cells infected with VSV-GFP (MOI of 10 PFU/cell) taken 
at the indicated times. (E) Quantification of the intensity of GFP associated fluorescence per GFP positive 
cell (arbitrary units, a.u.). Data are mean values + /− SE from at least three different experiments. *p < 0.05, 
**p < 0.01, ***p < 0.001 Student’s t test.
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cytokines, chemokines, extracellular matrix remodeling enzymes, and growth factors that modify the tissue 
microenvironment. Some of these factors have a known role in the innate immune response16. Therefore, we 
hypothesized that the senescence-induced antiviral response could be potentially mediated by the SASP. To 
evaluate this hypothesis, we examined the effect of senescent conditioned media (CM) on VSV replication. We 
first characterized the SASP produced by A549 cells induced to senesce by bleomycin treatment. The expression 
of different SASP components, including some interferon genes (IFNa, IFNb, and IFNabR), was measured by 
qRT-PCR, confirming the increased levels of several of these factors (Fig. 5A). Then, A549 cells were incubated 
with CM from bleomycin-induced senescent or control A549 cells for 24 h, and cells were then infected with VSV 
at different MOIs. Evaluation of the cytopathic effect 24 h after infection revealed that cells incubated with the 
senescent CM showed a significantly higher percentage of viable cells than those incubated with control CM from 
non-senescent cells at a MOI of 1 PFU/cell (Fig. 5B) (77.01% in cells cultured with senescent CM compared to 
56.59% when cultured in control CM, p = 0.008). This increased protection conferred by the senescent medium 
was not as high as the protection observed directly using bleomycin-induced senescent A549 cells or when inter-
feron was added to the medium as a control. This indicates a higher resistance of cells to VSV infection when 
cultured in the presence of senescent CM. Similarly, we also observed that incubation of MEFs with CM from 
replicative senescent cells increased viability 24 h after infection with VSV (MOI of 0.01 or 10 PFU/cell) (Fig. 5C). 
All together, these results suggest that the SASP has at least a partial role in the control of virus infection mediated 
by cell senescence.
Senescence induction in vivo restricts viral infection in mice. Our findings clearly indicated that 
replication of VSV was significantly impaired in senescent cells in culture. To substantiate these observations, 
we decided to evaluate the putative antiviral activity of cell senescence in vivo. For this, bleomycin or PBS con-
trol was administered intratracheally to mice in order to induce lung fibrosis and cell senescence as previously 
described13. Twenty one days after treatment, mice were infected intranasally with VSV (1 × 105 PFU/mice), and 
at 3 or 6 days after infection mice were sacrificed, and lungs were removed to determine viral titers. First, we 
evaluated the presence of senescent cells in the lungs of treated mice by performing whole-mount SA-beta-gal 
staining. Stained lungs were embedded in paraffin, sectioned and further stained to reveal fibrosis using mas-
son trichrome staining, and to detect VSV particles by immunohistochemistry (IHC). As shown in Fig. 6A, 
lungs from bleomycin-treated mice presented clear signs of fibrosis as judged by masson trichrome staining, as 
expected. At the same time, the fibrotic bleomycin-treated lungs showed a strong positive SA-beta-gal staining in 
consecutive sections, in comparison with the negative staining of lungs from control PBS-treated mice (Fig. 6A). 
We then determine the viral titers recovered from lung extracts and showed that, at 3 days post-infection, similar 
Figure 5. The senescence-induced antiviral response is partially mediated by the SASP. (A) Characterization 
of the expression of different SASP factors by qRT-PCR relative to GAPDH (x10−3) in control untreated (black 
bars) or senescent bleomycin-treated (white bars) A549 cells. (B) Cell viability of A549 cells cultured with 
conditioned medium (CM) from control untreated or senescent bleomycin-treated A549, after VSV infection 
at different MOIs. Viability of senescent bleomycin-treated A549 cells or A549 cells cultured in the presence 
of interferon are shown as controls. (C) Cell viability of MEFs cultures with CM from control early passage 
or senescent late passage MEFs, after VSV infection at MOIs of 0.01 or 10 PFU/cell relative to mock-infected 
cells. Data are mean values + /− SE from at least three different experiments. *p < 0.05, **p < 0.01, ***p < 0.001 
Student’s t test.
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VSV titers were detected in the lungs of mice independently of the administration of bleomycin or PBS (Fig. 6B). 
Interestingly however, we observed a clear difference in the viral titers measured in the control group at 6 days 
after infection compared to the senescence group (Fig. 6B). In particular, we could not detect VSV in any of the 
bleomycin-treated mice at 6 days after infection, while control mice still continued producing high titers of virus. 
These results were corroborated by IHC against VSV in lung sections stained in parallel with masson trichrome 
and SA-beta-gal. As shown in Fig. 6A, at 6 days post-infection, lungs from bleomycin-treated mice show very 
weak, if any, signal of viral infection, while the control tissue was clearly positive by IHC for VSV (22.89% positive 
cells in control versus 2.5% in bleomycin-treated lungs). These results indicated that cell senescence could func-
tion as an efficient mechanism to control virus replication in vivo.
Previous studies have indicated that SASP production leads to clearance of senescent cells via recruitment of 
innate immune cells17,18. Thus, we reasoned that the viral clearance observed in bleomycin-treated mice at day 6 
could be dependent, at least to some extent, on the removal of infected cells by infiltrating immune cells. To test 
Figure 6. Senescence induction in vivo restricts viral infection in mice. (A) Lung sections from mice 
intratracheally treated with PBS (left panels) as control or bleomycin (right panels) to induce senescence, 
stained with masson trichrome (upper panels), SA-beta-gal (middle panels), of IHC against VSV-G (lower 
panels). (B) Viral titers (PFU/gr) determined from lungs of mice intratracheally treated with PBS (black bars) 
as control or bleomycin (white bars) to induce senescence, after 3 or 6 days of intranasal administration of VSV. 
(C) Characterization of immune cell populations in lungs from mice intratracheally treated with PBS (black 
bars) as control or bleomycin (white bars) to induce senescence, after 3 or 6 days of intranasal administration of 
VSV.
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this hypothesis, we utilized multiparametric flow cytometry to determine the phenotype of cells in the broncho-
alveolar lavage (BAL) of treated and control mice after VSV infection. Our results indicated that both NK cells 
as well as conventional DCs (CD11b+ and CD103+) were significantly upregulated in the BAL of VSV-infected 
mice treated with bleomycin (Fig. 6C). While these findings do not imply causality, they strongly suggest that 
mechanistically, the SASP influence the recruitment of immune cells with capacity to clear virus from the sites of 
primary infection.
Discussion
Cellular senescence had a widely recognized status as a stress response mechanism triggered to prevent excessive 
proliferation of damaged cells caused either by accumulation of rounds of cell division or by hyperproliferative 
signals emanating from mutated oncogenes within the cell2. This concept was expanded to include also external 
signals such as chemotherapeutic drugs or wound healing. The recent discovery of programmed cell senescence 
operating during embryo development opened even further our view of cell senescence3,4. In this context, cell 
senescence operates as a morphogenic force that relies on secreted factors to recruit immune cells to clear out 
unneeded cells to allow for cell replacement, among other possible functions5. This basic mechanism might have 
been retained by evolution to operate during adulthood in settings such as cancer prevention or tissue repair. 
The stable cell cycle arrest and the release of proinflammatory cytokines and chemokines that characterizes cell 
senescence may evoke features of antiviral responses. Reinforcing this idea, numerous viruses have evolved mech-
anisms to interfere with senescence, a fact that might be interpreted as a viral strategy to escape from the cellular 
antiviral system8. Here, we wanted to explore the antiviral power of cell senescence, using VSV as a model and 
testing different senescence stimuli in primary or tumor cells, of mouse or human origin.
Our observations clearly establish that, independently of the trigger, senescence reduces the replication of 
VSV. This translates into low viral titers recovered from supernatants of infected cells, reduced viral protein 
synthesis, or decreased apoptosis after infection in senescent cells. Furthermore, we observed that senescence 
restricts the infectivity of VSV. Incubation with conditioned medium produced by senescent cells is enough to 
confer protection to proliferating cells against virus infection, indicating that this antiviral response is at least in 
part mediated by a complex secretory response that characterizes cell senescence, and known as the SASP. This 
senescence-mediated antiviral activity was validated in vivo when control or bleomycin-treated mice were chal-
lenged with VSV. Importantly, lungs from in vivo bleomycin-induced senescence mice showed no signs of viral 
particles after 6 days of infection compared to the high levels of virus detected in control mice. This suggests that 
the senescence derived SASP could be participating in the activation and recruitment of immune cells to the site 
of infection. A similar role of SASP promoting clearance of damaged cells from tissues and allowing for repair 
has been previously described for cell senescence in cancer or wound healing settings5. This new function of cell 
senescence as an antiviral mechanism provides new links between antitumor and antiviral immunity.
Materials and Methods
Cells, virus, reagents and mice. Wild type mouse embryo fibroblasts (WT MEFs) were extracted from 
13.5 days embryos and cultured in complete medium (Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma) 
supplemented with 10% heat inactivated foetal bovine serum (FBS, Sigma), 1% penicillin/streptomycin (10.000 
U penicillin/10 mg streptomycin, Sigma) and 2 mM L-glutamine (200 mM, Sigma), at 37 °C and in 20% oxygen 
and 5% CO2. Cells were serially passaged until they entered senescence. BSC-40, A549, and MCF7 cells were 
maintained in complete medium. Infections were carried out using VSV of Indiana strain or recombinant VSV 
expressing GFP (rVSV-GFP) kindly provided by Dr. Adolfo Garcia-Sastre (Mount Sinai School of Medicine), and 
virus yields were measured by plaque assays in BSC-40 cells. Cells were treated with 50 μ g/ml bleomycin (15 UI, 
Nippon Kayaku) for 5 days to induce senescence. Mice (C57BL/6) were housed at the serum pathogen-free (SPF) 
barrier area of CIMUS-USC. All experiments were carried out in compliance with Principles of Laboratory 
Animal Care of national laws, and all animal procedures were performed according to protocols approved by 
the Santiago de Compostela University Bioethics Committee (protocol number 15005AE/07/01/02/05 C/AVF2).
SA β-gal and masson trichrome stainings. Senescence-associated β -galactosidase (SA-beta-gal) activ-
ity was determined as reported previously11. Whole-mount SA-beta-gal staining was performed as previously 
described3. After staining, tissue was embedded in paraffin and sectioned for masson trichrome staining or 
immunohistochemistry with antibody against VSV-G. Photographs were taken in an Axio Vert.A1 microscope 
(Zeiss) with ZEN software.
Antibodies. Anti-VSV M antibody was from KeraFAST, anti-p53 antibody (DO-1) and anti-p21 (F-5) were 
from Santa Cruz (#sc126 and sc-6246, respectively), anti-P-Erk (P-p44/42) and anti-Erk (p44/42) were both from 
Cell Signalling Technologies (#4370 and #4695, respectively), anti-Pan-Ras (OP40) was from Millipore, anti-actin 
was from MP Biomedicals, and anti-tubulin antibody was from Serotec. VSV-G antibody was a generous gift of 
Dr. I Ventoso (CBMSO, Madrid).
Protein and RNA expression analysis. For protein expression analysis, cell extracts were prepared 
using RIPA buffer (150 mM NaCl, 10 mM Tris-HCl pH 7.5, 0.1% SDS, 1% Triton X100, 5 mM EDTA pH 8.0, 1% 
Deoxycholate and sodium salt containing protease inhibitors), and appropriate volumes of cell extracts, adjusted 
to represent the same amount of total cellular protein (30 μ g), were electrophoresed in 12% polyacrylamide gels. 
After electrophoretic transfer to a PVDF membrane at 100 V for 1 h at 4 °C, the membrane was blocked with 5% 
milk in TTBS (20 mM Tris-HCl pH7.5, 150 mM NaCl, 0.05% Tween-20) for 1 h at room temperature. Membranes 
were incubated at 4 °C overnight with primary antibodies as indicated. Incubation with the appropriate secondary 
antibodies conjugated to HRP was followed by visualization using the ECL system.
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To measure RNA expression, total RNA was extracted using the NucleoSpin® RNA kit (Macherey-Nagel) 
following the indications of the provider and DNAse treatment. After nanodrop RNA quantification, the RNA 
was retrotranscribed into cDNA according to the manufacturer’s protocol (High-Capacity cDNA Reverse 
Transcription Kit, Applied Biosystems). Quantitative Real Time-PCR was performed using SYBR Green Power 
PCR Master Mix (Applied Biosystems) in an Mx3005 P real-time PCR system (Agilent technologies Stratagene). 
Relative quantitative RNA was normalized using the housekeeping gene GADPH. Primer sequences are available 
from the authors upon request.
Immunofluorescence and time-lapse microscopy. Immunofluorescence staining was performed as 
previously described19. Analysis of the samples was carried out on an Axio Vert.A1 microscope (Zeiss) with ZEN 
software. For time-lapse microscopy, A549 cells grown on culture-insert microwells (80406, Ibidi) were infected 
with VSV-GFP at a MOI of 10 PFU/cell. Pictures were taken every 10 min starting at 5 hours post infection (hpi) 
and until 18 hpi on a Nikon BioStation microscope using BioStation IM software (v2.12, build 136, Nikon). 
We quantified the intensity of the GFP associated fluorescente per infected cell using NIS-Elements BR (v.4.13, 
Nikon).
Flow cytometry. Cells infected with rVSV-GFP were fixed in 2% paraformaldehyde for 20 min. The percent 
of GFP positive cells was determined by flow cytometry, using a FACScalibur cytometer (BD Biosciences).
Apoptosis quantification. Apoptosis was quantified by flow cytometry using the caspase-3, active form, 
mAb Apoptosis kit from BD Pharmigen, according to manufacturer’s protocol.
Effect of conditioned media on VSV replication. A549 cells were forced into senescence by cultiva-
tion with bleomycin for 5 days. The cultivation medium was then removed and the cells were cultivated in fresh 
drug-free 2% FBS medium for the following 3 days. The conditioned medium produced by senescent cells was fil-
tered through PVDF syringe driven filters (0.22 μ m, Jet-Biofil) and transferred to normal proliferating A549 cells. 
Control cells were treated in the same manner by conditioned medium recovered from normal A549 cells. After 
24 h of cultivation in conditioned medium, cells seeded into 96-well plates were infected with VSV at different 
MOIs. After 24 h of infection, the medium was removed and cytolysis was determined by crystal violet staining 
as described previously20. The percentage of viable cells was calculated assuming the survival rate of uninfected 
cells to be 100%. Conditioned medium from replicative senescent MEFs or from proliferating MEFs was assayed 
in a similar manner. A549 cells or MEFs treated with 500 U/mL of human or mouse β -interferon, respectively, 
were included as control.
In vivo analysis of viral infection. Eight weeks old littermate male C57BL/6 mice were used in this study. 
To induce pulmonary fibrosis, bleomycin was administered intratracheally at a dose of 5 mg/Kg body weight 
(n = 7 mice). A control group (n = 13 mice) received the same volume of sterile saline only. At 21 after treatment, 
6 mice per group were intranasally infected with a single dose of VSV (105 PFU), and at 3 or 6 days after infec-
tion, mice were sacrificed and their lungs removed. In addition, we collected bronchoalveolar lavages (BAL) for 
immune cell population analysis. A fraction of the lungs was used for histological analysis as mentioned above, 
and the rest was immediately frozen for viral titer determination.
Statistical analysis. For statistical analysis between control and different groups the Student’s t test was 
applied. The significance level chosen for the statistical analysis was p < 0.05.
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